| Size | Price | |
|---|---|---|
| Other Sizes |
| Targets |
4,6-Dihydroxypyrimidine does not have a defined primary drug target as it is primarily a biochemical reagent rather than a therapeutic agent. As a pyrimidine derivative, it may interact with enzymes involved in pyrimidine metabolism or nucleic acid synthesis in cell-based assays. The compound can serve as a precursor or building block for the synthesis of more complex pyrimidine-containing pharmaceuticals. No specific receptor or enzyme targets have been characterized for this compound in pharmacological literature.
|
|---|---|
| ln Vitro |
No specific in vitro pharmacological activity data are available for 4,6-dihydroxypyrimidine as a drug candidate. In research applications, the compound is used as a biochemical reagent and synthetic intermediate. It may be evaluated in cell-based assays for its effects on pyrimidine-related metabolic pathways or as a precursor for the synthesis of bioactive molecules. Typical working concentrations and incubation conditions are determined based on the specific experimental design.
|
| ln Vivo |
No specific in vivo pharmacological activity data have been documented for 4,6-dihydroxypyrimidine. The compound is used exclusively as a research reagent and has not been developed as a therapeutic agent. For animal studies, the compound can be formulated using standard injection vehicles such as DMSO:Tween 80:saline mixtures for administration. Dosing protocols should be established based on the specific research objectives and approved animal protocols.
|
| Enzyme Assay |
For non-cellular enzyme or receptor binding assays involving 4,6-dihydroxypyrimidine, the compound can be tested as a potential substrate, inhibitor, or modulator of pyrimidine-metabolizing enzymes. Typical protocols involve incubating the compound with purified enzyme preparations in appropriate buffer systems at 37°C, followed by detection of enzymatic activity using spectrophotometric, fluorometric, or chromatographic methods. Control reactions without the compound and with known inhibitors should be included for reference.
|
| Cell Assay |
For in vitro cell-based studies, 4,6-dihydroxypyrimidine is typically dissolved in DMSO to prepare a stock solution, then diluted in cell culture medium to the desired working concentrations. Cells are cultured under standard conditions (37°C, 5% CO2) and treated with the compound for various durations. Cellular responses can be assessed using assays for viability (MTT, CCK-8), proliferation, apoptosis, or specific metabolic markers. Appropriate vehicle controls and positive controls should be included in the experimental design.
|
| Animal Protocol |
For in vivo animal studies, 4,6-dihydroxypyrimidine can be administered via injection using formulations such as DMSO:Tween 80:saline (10:5:85) or other suitable vehicles. The compound powder should be stored at -20°C for up to 3 years or at 4°C for up to 2 years; in solvent, it is stable at -80°C for 6 months or at -20°C for 1 month. Dosing solutions should be freshly prepared and administered according to the specific protocol with appropriate control groups.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties of 4,6-dihydroxypyrimidine have not been characterized as it is a research reagent. The compound has a logP of -1.9, indicating hydrophilic character. It has 2 hydrogen bond donors and 3 hydrogen bond acceptors. Storage recommendations: powder at -20°C for 3 years or 4°C for 2 years; in solvent at -80°C for 6 months or -20°C for 1 month. Solubility: may dissolve in DMSO; other solvents such as water, ethanol, or DMF may also be tested.
|
| Toxicity/Toxicokinetics |
Toxicological data for 4,6-dihydroxypyrimidine are limited as it is a research reagent. The compound is for research use only and not for human therapeutic use. Standard laboratory safety precautions should be followed when handling this chemical. No specific LD50 values, carcinogenicity data, or reproductive toxicity studies have been reported in the literature. The compound should be handled with appropriate personal protective equipment.
|
| Additional Infomation |
4,6-Dihydroxypyrimidine is a hydroxypyrimidine.
4,6-Dihydroxypyrimidine (CAS 1193-24-4) is a hydroxypyrimidine biochemical reagent used in biomedical research. It is also known as 4,6-pyrimidinediol, 6-hydroxy-4(1H)-pyrimidinone, and 4(3H)-pyrimidinone, 6-hydroxy-. The compound has a density of 1.5±0.1 g/cm³, boiling point of 358.5±22.0°C, and flash point of 170.6±22.3°C. No clinical trials or regulatory approvals exist for human use; the product is exclusively for research purposes. |
| Molecular Formula |
C4H4N2O2
|
|---|---|
| Molecular Weight |
112.09
|
| Exact Mass |
112.027
|
| CAS # |
1193-24-4
|
| PubChem CID |
14512
|
| Appearance |
Yellow to orange solid powder
|
| Density |
1.5±0.1 g/cm3
|
| Boiling Point |
358.5±22.0 °C at 760 mmHg
|
| Melting Point |
>300 °C(lit.)
|
| Flash Point |
170.6±22.3 °C
|
| Vapour Pressure |
0.0±0.8 mmHg at 25°C
|
| Index of Refraction |
1.640
|
| LogP |
-1.9
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
3
|
| Rotatable Bond Count |
0
|
| Heavy Atom Count |
8
|
| Complexity |
171
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
O([H])C1=C([H])C(N([H])C([H])=N1)=O
|
| InChi Key |
DUFGYCAXVIUXIP-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C4H4N2O2/c7-3-1-4(8)6-2-5-3/h1-2H,(H2,5,6,7,8)
|
| Chemical Name |
4-hydroxy-1H-pyrimidin-6-one
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 8.9214 mL | 44.6070 mL | 89.2140 mL | |
| 5 mM | 1.7843 mL | 8.9214 mL | 17.8428 mL | |
| 10 mM | 0.8921 mL | 4.4607 mL | 8.9214 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
